MedTrace Logo

The Therapeutic Effects of Topiramate and Metformin on Second Generation Antipsychotics-induced Obesity

NCT01384279 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2012-02-24

No results posted yet for this study

Summary

The primary aim of the study is to investigate the efficacy of metformin and topiramate on second-generation antipsychotic-induced obesity. The secondary domain we look at is the adverse effects of both drugs. The investigators hypothesize that metformin and topiramate are effective in treating obesity induced by second-generation antipsychotics.

Conditions

Interventions

DRUG

metformin, topiramate

metformin 250 mg/d is gradually increased to 1000 mg/d over four weeks, and topiramate 50 mg/d is gradually increased to 200 mg/d over four weeks

Sponsors & Collaborators

  • Beitou Armed Forces Hospital, Taipei, Taiwan

    lead OTHER_GOV

Principal Investigators

  • Chiang Kuo-Tung, M.D. · Department of Psychiatry, Beitou Armed Forces Hospital, Taipei, Taiwan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2011-12-31
Completion
2012-01-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01384279 on ClinicalTrials.gov